Lewis Branscomb Explains How Dukakis Will Bolster Research

Branscomb The first problem is simply for the administration to organize itself to deal with issues of science and technology in a professional and effective manner. That is something that in my opinion the last several administrations have progressively been doing less and less well. Q How might this be accomplished? Will Dukakis be able to do it? Branscomb The president has to set the tone with his cabinet when he fills those jobs, but one thing that Dukakis has committed himself to is to u

| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Branscomb The first problem is simply for the administration to organize itself to deal with issues of science and technology in a professional and effective manner. That is something that in my opinion the last several administrations have progressively been doing less and less well.

Q How might this be accomplished? Will Dukakis be able to do it?

Branscomb The president has to set the tone with his cabinet when he fills those jobs, but one thing that Dukakis has committed himself to is to use his science adviser to review senior level technical appointments to executive jobs. I think that’s absolutely essential. I don’t think that the science adviser needs a veto power. But I think all of those recommendations must pass through his office after they have cleared the White House personnel office. They should then go to the president with an attached memorandum from the science adviser ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies